Yoshimura Teizo, Imamichi Tomozumi, Weiss Jonathan M, Sato Miwa, Li Liangzhu, Matsukawa Akihiro, Wang Ji Ming
Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA; Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Laboratory of Human Retrovirology and Immunoinformatics, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research , Frederick, MD , USA.
Front Immunol. 2016 Jan 20;7:2. doi: 10.3389/fimmu.2016.00002. eCollection 2016.
Monocyte chemoattractant protein-1 (MCP-1)/CCL2 plays an important role in the initiation and progression of cancer. We previously reported that in 4T1 murine breast cancer, non-tumor stromal cells, including macrophages, were the major source of MCP-1. In the present study, we analyzed the potential mechanisms by which MCP-1 is upregulated in macrophages infiltrating 4T1 tumors. We found that cell-free culture supernatants of 4T1 cells (4T1-sup) markedly upregulated MCP-1 production by peritoneal inflammatory macrophages. 4T1-sup also upregulated other MCPs, such as MCP-3/CCL7 and MCP-5/CCL12, but modestly upregulated neutrophil chemotactic chemokines, such as KC/CXCL1 or MIP-2/CXCL2. Physicochemical analysis indicated that an approximately 20-30 kDa 4T1 cell product was responsible for the capacity of 4T1-sup to upregulate MCP-1 expression by macrophages. A neutralizing antibody against granulocyte/macrophage colony-stimulating factor (GM-CSF), but not macrophage CSF, almost completely abrogated MCP-1-inducing activity of 4T1-sup, and recombinant GM-CSF potently upregulated MCP-1 production by macrophages. The expression levels of GM-CSF in 4T1 tumors in vivo were higher than other tumors, such as Lewis lung carcinoma. Treatment of mice with anti-GM-CSF antibody significantly reduced the growth of 4T1 tumors at the injection sites but did not reduce MCP-1 production or lung metastasis in tumor-bearing mice. These results indicate that 4T1 cells have the capacity to directly upregulate MCP-1 production by macrophages by releasing GM-CSF; however, other mechanisms are also involved in increased MCP-1 levels in the 4T1 tumor microenvironment.
单核细胞趋化蛋白-1(MCP-1)/CCL2在癌症的发生和发展中起重要作用。我们之前报道过,在4T1小鼠乳腺癌中,包括巨噬细胞在内的非肿瘤基质细胞是MCP-1的主要来源。在本研究中,我们分析了浸润4T1肿瘤的巨噬细胞中MCP-1上调的潜在机制。我们发现4T1细胞的无细胞培养上清液(4T1-sup)显著上调了腹膜炎性巨噬细胞的MCP-1产生。4T1-sup还上调了其他MCP,如MCP-3/CCL7和MCP-5/CCL12,但对中性粒细胞趋化性趋化因子,如KC/CXCL1或MIP-2/CXCL2的上调作用较小。物理化学分析表明,一种约20-30 kDa的4T1细胞产物负责4T1-sup上调巨噬细胞MCP-1表达的能力。抗粒细胞/巨噬细胞集落刺激因子(GM-CSF)的中和抗体,而非巨噬细胞集落刺激因子的中和抗体,几乎完全消除了4T1-sup诱导MCP-1的活性,并且重组GM-CSF强烈上调了巨噬细胞的MCP-1产生。体内4T1肿瘤中GM-CSF的表达水平高于其他肿瘤,如Lewis肺癌。用抗GM-CSF抗体治疗小鼠显著降低了注射部位4T1肿瘤的生长,但并未降低荷瘤小鼠的MCP-1产生或肺转移。这些结果表明,4T1细胞能够通过释放GM-CSF直接上调巨噬细胞的MCP-1产生;然而,其他机制也参与了4T1肿瘤微环境中MCP-1水平的升高。